Myopathies related to systemic sclerosis: A case-control study of associated clinical and immunological features

Scandinavian Journal of Rheumatology

Volumn 39, Issue 6, 2010, Pages 498-505

  Ranque, B ^a   Berezne A ^a   Le Guern, V ^a   Pagnoux, C ^a   Allanore, Y ^b   Launay, D ^c   Hachulla, E ^c   Authier, F J ^d   Gherardi, R ^d   Kahan, A ^b   Cabane, J ^e   Guillevin, L ^a   Mouthon, L ^a  

^a Public Assistance Hospitals of Paris ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY;

ADULT; ARTICLE; CASE CONTROL STUDY; CENTROMERE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE DURATION; ELECTROMYOGRAPHY; FEMALE; FORCED VITAL CAPACITY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOLOGICAL PARAMETERS; MALE; MULTICENTER STUDY; MUSCLE; MYOPATHY; POLYMYOSITIS; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ARRHYTHMIAS, CARDIAC; AUTOANTIBODIES; CASE-CONTROL STUDIES; CREATINE KINASE; FEMALE; FRANCE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCULAR DISEASES; POLYMYOSITIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; STROKE VOLUME; VITAL CAPACITY; YOUNG ADULT;

EID: 78649701343     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009741003774626     Document Type: Article

References (33)

1. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;2:152-7.
2. Servettaz A, Agard C, Tamby MC, Guilpain P, Guillevin L, Mouthon L. [Systemic sclerosis: pathophysiology of a multifaceted disease], in French. Presse Med 2006;35:1903-15. (Pubitemid 44915261)
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
5. Medsger TA Jr, Rodnan GP, Moossy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968;11:554-68.
6. Thompson JM, Bluestone R, Bywaters E G L, Dorling J, Johnson M. Skeletal muscle involvement in systemic sclerosis. Ann Rheum Dis 1969;28:281-8.
7. Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 1978;21:62-71.
8. West SG, Killian PJ, Lawless OJ. Association of myositis and myocarditis in progressive systemic sclerosis. Arthritis Rheum 1981;24:662-8.
9. Hausmanowa-Petrusewicz I, Jablonska S, Blaszczyk M, Matz B. Electromyographic findings in various forms of progressive systemic sclerosis. Arthritis Rheum 1982;25:61-5.
10. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993;125:194-203.
11. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 2005;24:99-102.
12. Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009;68:1474-7.
13. Ranque B, Authier FJ, Berezne A, Guillevin L, Mouthon L. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 2007;1108:268-82.
14. Olsen NJ, King LE Jr, Park JH. Muscle abnormalities in scleroderma. Rheum Dis Clin North Am 1996;22:783-96.
15. Ringel RA, Brick JE, Brick JF, Gutmann L, Riggs JE. Muscle involvement in the scleroderma syndromes. Arch Intern Med 1990;150:2550-2.
16. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
17. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology (Oxford) 1999;38:397-400.
18. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
19. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
20. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
21. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
22. Allanore Y, Vignaux O, Arnaud L, Puechal X, Pavy S, Duboc D, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65:249-52.
23. Steen V. The heart in systemic sclerosis. Curr Rheumatol Rep 2004;6:137-40.
24. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006;45(Suppl 4): iv14-17. (Pubitemid 44446757)
25. Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008;20:697-702.
26. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-84.
27. Russell ML, Hanna WM. Ultrastructure of muscle microvasculature in progressive systemic sclerosis: relation to clinical weakness. J Rheumatol 1983;10:741-7.
28. Scarpelli M, Montironi R, Tulli D, Sisti S, Matera G, Magi Galluzzi C, et al. Quantitative analysis of quadriceps muscle biopsy in systemic sclerosis. Pathol Res Pract 1992;188:603-6.
29. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-19.
30. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
31. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998;17:48-54.
32. Jablonska S, Blaszczyk M. Scleromyositis: a scleroderma/polymyositis overlap syndrome. Clin Rheumatol 1998;17; 6:465-7.
33. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum autoantibody to the nucleolar antigen PMScl. Clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211-17.